CN115103836A - 制备手性苯并二氮杂卓酮衍生物的方法 - Google Patents

制备手性苯并二氮杂卓酮衍生物的方法 Download PDF

Info

Publication number
CN115103836A
CN115103836A CN202180014113.5A CN202180014113A CN115103836A CN 115103836 A CN115103836 A CN 115103836A CN 202180014113 A CN202180014113 A CN 202180014113A CN 115103836 A CN115103836 A CN 115103836A
Authority
CN
China
Prior art keywords
compound
formula
solvent
combination
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180014113.5A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯多佛·M·西马鲁斯蒂
阿南德库马尔·马丹拉尔·拉赫蒂
马丹·拉贾·戈帕尔·雷迪·德拉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yimi Rumei Co ltd
Original Assignee
Ayala Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ayala Pharmaceuticals Inc filed Critical Ayala Pharmaceuticals Inc
Publication of CN115103836A publication Critical patent/CN115103836A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C07D243/26—Preparation from compounds already containing the benzodiazepine skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C07D243/30—Preparation including building-up the benzodiazepine skeleton from compounds already containing hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180014113.5A 2020-02-16 2021-02-16 制备手性苯并二氮杂卓酮衍生物的方法 Pending CN115103836A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062977316P 2020-02-16 2020-02-16
US62/977,316 2020-02-16
PCT/US2021/018137 WO2021163676A1 (en) 2020-02-16 2021-02-16 Methods of preparing chiral benzodiazepinone derivatives

Publications (1)

Publication Number Publication Date
CN115103836A true CN115103836A (zh) 2022-09-23

Family

ID=77291712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180014113.5A Pending CN115103836A (zh) 2020-02-16 2021-02-16 制备手性苯并二氮杂卓酮衍生物的方法

Country Status (11)

Country Link
US (2) US12503449B2 (https=)
EP (1) EP4107148A4 (https=)
JP (1) JP2023513731A (https=)
KR (1) KR20220143094A (https=)
CN (1) CN115103836A (https=)
AU (1) AU2021218456A1 (https=)
BR (1) BR112022016249A2 (https=)
CA (1) CA3171651A1 (https=)
IL (1) IL295572A (https=)
MX (1) MX2022010079A (https=)
WO (1) WO2021163676A1 (https=)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253571A1 (en) * 1986-07-14 1988-01-20 Merck & Co. Inc. Process for resolution and race mization of amines with acidic alpha-hydrogens
WO2010073253A1 (en) * 2008-12-22 2010-07-01 Natco Pharma Limited Method for preparing an optically active frovatriptan
US20150045575A1 (en) * 2012-03-30 2015-02-12 Merck Sharp & Dohme Corp. Process for preparing fluoroleucine alkyl esters
CN104822677A (zh) * 2012-09-21 2015-08-05 百时美施贵宝公司 氟烷基-1,4-苯并二氮杂*酮化合物
CN105308030A (zh) * 2012-09-21 2016-02-03 百时美施贵宝公司 烷基、氟烷基-1,4-苯并二氮杂*酮化合物
CN105439939A (zh) * 2015-11-12 2016-03-30 四川恒康科技发展有限公司 一种(S)-N-Boc-3-羟基哌啶的合成方法
CN106660949A (zh) * 2015-02-17 2017-05-10 株式会社爱茉莉太平洋 N‑[4‑(1‑氨基乙基)‑苯基]‑磺酰胺衍生物的手性拆分方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9000386A (nl) * 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
JPH0751555B2 (ja) 1992-04-15 1995-06-05 キヤノン株式会社 ジイモニウム塩化合物
BRPI0520554A2 (pt) * 2005-09-19 2009-06-13 Arrow Therapeutics Ltd uso de uma benzodiazepina ou um sal farmaceuticamente aceitável do mesmo, método para tratar ou prevenir uma infecção por hcv em um paciente, derivado de benzodiazepina ou um sal famaceuticamente aceitável do mesmo, e, composição farmacêutica
EP2897942B1 (en) 2012-09-21 2016-08-31 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch inhibitors
TWI614238B (zh) * 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253571A1 (en) * 1986-07-14 1988-01-20 Merck & Co. Inc. Process for resolution and race mization of amines with acidic alpha-hydrogens
WO2010073253A1 (en) * 2008-12-22 2010-07-01 Natco Pharma Limited Method for preparing an optically active frovatriptan
US20150045575A1 (en) * 2012-03-30 2015-02-12 Merck Sharp & Dohme Corp. Process for preparing fluoroleucine alkyl esters
CN104822677A (zh) * 2012-09-21 2015-08-05 百时美施贵宝公司 氟烷基-1,4-苯并二氮杂*酮化合物
CN105308030A (zh) * 2012-09-21 2016-02-03 百时美施贵宝公司 烷基、氟烷基-1,4-苯并二氮杂*酮化合物
CN106660949A (zh) * 2015-02-17 2017-05-10 株式会社爱茉莉太平洋 N‑[4‑(1‑氨基乙基)‑苯基]‑磺酰胺衍生物的手性拆分方法
CN105439939A (zh) * 2015-11-12 2016-03-30 四川恒康科技发展有限公司 一种(S)-N-Boc-3-羟基哌啶的合成方法

Also Published As

Publication number Publication date
MX2022010079A (es) 2022-09-02
US20250346565A1 (en) 2025-11-13
BR112022016249A2 (pt) 2022-10-11
CA3171651A1 (en) 2021-08-19
EP4107148A1 (en) 2022-12-28
WO2021163676A1 (en) 2021-08-19
EP4107148A4 (en) 2024-05-15
IL295572A (en) 2022-10-01
US20230108536A1 (en) 2023-04-06
US12503449B2 (en) 2025-12-23
AU2021218456A1 (en) 2022-09-22
KR20220143094A (ko) 2022-10-24
JP2023513731A (ja) 2023-04-03

Similar Documents

Publication Publication Date Title
JP4172717B2 (ja) 置換２，５−ジアミノ−３−ヒドロキシヘキサンの製造方法
MXPA04010771A (es) Procedimiento para preparar (-butirolactamas y (-amino acidos muy funcionalizados.
MX2008003428A (es) Pirrolidin -2-onas sustituidas en la posicion 4 y sus usos.
CN107250100B (zh) 制备nep抑制剂的工艺和中间体
WO2017191539A1 (en) Process for the preparation dl-proline co-crystal of dapagliflozin
CN101563329A (zh) 用于制备4，4’-（1-甲基-1，2-乙二基）-双-（2，6-哌嗪二酮）的新方法
Cabrera et al. Homochiral l-prolinamido-sulfonamides and their use as organocatalysts in aldol reactions
CN115103836A (zh) 制备手性苯并二氮杂卓酮衍生物的方法
US8742162B2 (en) Method for producing optically active 1-amino-2-vinylcyclopropanecarboxylic acid ester
EP3567027B1 (en) Method for producing n-benzyl-2-bromo-3-methoxypropionamide and intermediates thereof
JP7710717B2 (ja) 光学活性ピロリジン誘導体またはその酸性塩、光学活性α－カルボリン誘導体、およびそれらの製造方法
JP7837977B2 (ja) ４－（３，５－ジフルオロフェニル）－Ｎ－［３－（６－メチルピリミジン－４－イル）－３－アザビシクロ［３．２．１］オクタン－８－イル］－６，７－ジヒドロ－５Ｈ－［１，２，４］トリアゾロ［１，５－ａ］ピリミジン－２－アミンの調製のための方法
US5786500A (en) Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane
EP4387955A1 (en) Synthesis of brivaracetam
WO2006036498A2 (en) A process for the preparation of 1,3,5-trisubstituted pyrazoles via [3+2] cycloaddition
Melgar-Fernández et al. Resolution of 5-oxo-1-phenylpyrazolidine-3-carboxylic acid and synthesis of novel enantiopure amide derivatives
Yuasa et al. Enantioselective Synthesis of (S)-3-(4-Thiazolyl)-2-tert-butoxycarbonyl-aminoproplonic Acid: A Chiral Building Block for Renin Inhibitor
CN120247760A (zh) 末端n-氨基甲酸酯氮杂环丙烷的动力学拆分方法及(s)-巴氯芬的手性合成方法
JP2023553051A (ja) （９Ｓ）－Ｎ－［３－（６－メチルピリミジン－４－イル）－３－アザビシクロ［３．２．１］オクタン－８－イル］－９－（２，３，４－トリフルオロフェニル）－６，７，８，９－テトラヒドロ－５Ｈ－［１，２，４］トリアゾロ［１，５－ａ］アゼピン－２－アミンの調製のための方法、および、その固体形態
JP2023515000A (ja) パノビノスタットの製造方法
JP2005255610A (ja) 光学活性な３−アミノアスパラギン酸誘導体の製造方法
HK1181382A (en) Process for the preparation of dimiracetam
WO2006093354A1 (ja) (ｓ)−２−[３−(ｎ−{[４−(４−フルオロフェノキシ)フェニル]メチル}カルバモイル)−４−メトキシフェニルメチル]ブタン酸の製造中間体
HK1011677B (en) Intermediates for the preparation of a substituted 2,5-diamino -3-hydroxyhexane
HK1099774A (en) Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20251110

Address after: Washington State

Applicant after: Yimi Rumei Co.,Ltd.

Country or region after: U.S.A.

Address before: Delaware, USA

Applicant before: Ayala pharmaceutical Co.

Country or region before: U.S.A.